Articles tagged with Hemoglobin
Researchers identified five gene variants that could predict sickle cell disease severity and offer potential therapeutic targets. These variants influence fetal hemoglobin levels, which affect symptom severity in the disease.
Researchers at the University of Bonn have identified a new hemoglobin type that appears to transport less oxygen than normal. This discovery was made after examining two patients with low oxygen levels in their blood, who did not show any signs of cardiac defects. The new type of haemoglobin, named Haemoglobin Bonn, can distort oxygen...
Researchers have identified a novel small molecule therapy called senicapoc that shows efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia. Senicapoc, a Gardos channel blocker, works by limiting solute and water loss, thereby preserving RBC hydration.
Researchers discovered a genetic variant in the BCL11A gene associated with higher levels of fetal hemoglobin and milder beta-thalassemia symptoms. This finding has implications for developing targeted therapies to alleviate hemoglobin deficiencies in people with beta-thalassemia and sickle cell anemia.
A recent study published in the Clinical Journal of the American Society of Nephrology suggests that persistently low hemoglobin levels in dialysis patients increase their risk of death, while fluctuating levels do not. The research used data from nearly 160,000 patients to analyze the effects of hemoglobin variability on mortality rates.
Researchers developed a new indicator, Hb-Var, measuring hemoglobin level stability in dialysis patients, finding it strongly predicts mortality risk. Higher Hb-Var scores associated with increased death rates, even after adjusting for absolute hemoglobin levels and trends.
A team of researchers has made a breakthrough in understanding the mechanisms that regulate hemoglobin's ability to transport oxygen. By using sophisticated atomic calculation techniques, they have identified the factors that control hemoglobin's affinity for oxygen, which can now be used to design alterations of its structure.
A team of researchers from Wake Forest University has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that converts nitrite salt to the vasodilator nitric oxide. This reaction mechanism could have far-reaching implications for treating cardiovascular diseases.
A new predictive model using hemoglobin level, International Normalized Ratio, and penetrating injury mechanism can accurately predict which soldiers require massive blood transfusions, allowing for timely mobilization of resources. This model has been shown to reliably predict the need for massive transfusions in combat patients.
Researchers found that the human immune system uses hemoglobin to bind to HDL and create a toxin that clears trypanosomes from the body. This discovery could lead to better treatment options for cattle infections and provide insights into understanding why some parasites don't infect humans.
A study reveals that hemoglobin levels vary among dialysis patients due to negative feedback control systems and individual sensitivity to ESA treatment. The analysis suggests optimizing treatment systems on a rational basis to reduce variation in hemoglobin values and stabilize dose regimens.
Researchers discovered a genetic variation that enables adults to express higher levels of fetal hemoglobin, reducing their risk of Alzheimer's disease. The study also found that beta amyloid peptide has an affinity for adult hemoglobin, which may enhance its ability to wreak havoc in the brain.
Researchers at VCU have developed a unique anti-sickling agent called 5-HMF, which has shown promise in treating sickle cell disease by increasing the oxygen affinity of both normal and sickle hemoglobin. This breakthrough could lead to new drug treatments for the debilitating genetic blood disorder.
Researchers have discovered a new protein called neuroglobin in the brain that defends against oxygen deprivation and brain damage. This protein plays a protective role, ushering in nitric oxide to protect neuron survival and recovery.
Researchers analyzed data from 11 studies and found that blacks with diabetes had about 0.65% less A1C levels, a measure of blood sugar control, compared to whites. This disparity contributes to higher rates of diabetes complications among blacks.
A four-year study found chronically high blood sugar associated with increased risk of mild cognitive impairment (MCI) or dementia. Women with elevated glycosylated hemoglobin were four times more likely to develop MCI or dementia than those with lower levels.
Researchers found that men with the same hemoglobin levels before treatment experienced significantly different overall and progression-free survival depending on whether they were black or white. Anemic blacks fare worse than anemic whites, while blacks with high baseline hemoglobin fare better.
Researchers from University of North Carolina Health Care and N.C. State University develop a vaccine that protects animals from chancroid, a sexually transmitted disease that can enhance HIV transmission. The study suggests that a chancroid vaccine could be relatively easy to develop and may help reduce HIV transmission in Africa.
Researchers at Memorial Sloan Kettering Cancer Center have successfully treated sickle cell disease in human models using stem cell-based gene therapy with RNA interference. The treatment corrected the production of abnormal hemoglobin and restored normal blood flow, offering new hope for patients.
In the Phase 2 study, Aranesp demonstrated a significant erythroid response and improvements in hemoglobin levels and fatigue among low-risk MDS patients. The study found that 70% of patients with no prior erythropoietic agent use achieved an erythroid response and 67% reached target hemoglobin levels.
A Phase 3 study found that Aranesp treatment achieved and maintained target hemoglobin levels, reducing red blood cell transfusions by 24%. The extended dosing schedule may allow physicians to treat anemia on the same schedule as chemotherapy.
A study found that anemia is associated with a higher risk of death in the elderly, even among those with normal hemoglobin levels. Lower hemoglobin concentrations were linked to increased mortality risk, regardless of other factors.
Researchers at Medical College of Georgia have found that inhaling nitric oxide gas can help normalize a sickle cell patient's hemoglobin by restoring its natural charge and shape. This may prevent unhealthy clustering of hemoglobin S molecules and improve oxygen delivery to the body.
Purdue researchers led by Jorge H. Rodriguez are developing computational tools to simulate and predict biochemical reactions using quantum physics. This technique could help select the best potential new drug compounds and expand knowledge of life's fundamental processes.
Researchers at Boston Children's Hospital developed a new screening test, CHr, to detect iron deficiency in infants. The test identified 83% of iron-deficient infants correctly, compared to only 26% with the standard hemoglobin test.
A research team has identified the gene glutaredoxin 5 (grx5) as essential for hemoglobin synthesis in zebrafish and humans. The discovery reveals a new pathway involving iron-sulfur clusters, which is critical for heme production.
Patients with heart failure and low hemoglobin levels are at increased risk of complications, including hospitalization and mortality. Studies show that treating anemia may reduce the risk of death by up to 22% in these patients.
The study found that Medicare beneficiaries received lower rates of preventive services, with strong associations between practice type and revenue from Medicaid. Practices with less than 6% of revenue from Medicaid were more likely to provide certain preventive services, while those with high percentages were less likely.
Researchers discover hemoglobin's novel function as a nitrite reductase, generating nitric oxide to regulate vasodilation. Separate studies reveal that M cells are not necessary for oral tolerance induction, while bacterial infections can break B cell tolerance by activating self-reactive B cells.
A Phase 2 study of Aranesp(R) demonstrates a 77% overall response rate in low-risk MDS patients with anemia. Patients who had never received erythropoietic therapy responded well to Aranesp, while those with prior treatment showed continued efficacy.
Researchers found that abnormal distribution of PfEMP-1 protein on red blood cells containing hemoglobin C impairs malaria parasites' ability to cause disease symptoms. This may explain why individuals with at least one gene for hemoglobin C are less prone to severe malaria.
Symbiotic plant hemoglobins facilitate oxygen transport and energy metabolism in legume root nodules, allowing bacteria to fix atmospheric nitrogen. The proteins also maintain low-oxygen concentrations to protect the nitrogenase enzyme complex responsible for symbiotic nitrogen fixation.
Deep-sea tubeworms have adapted to thrive near hydrothermal vents by binding hydrogen sulfide molecules with zinc ions in their hemoglobin. This discovery could lead to the development of new oxygen carriers and medical applications.
Two studies find that high hemoglobin A1c levels are an independent risk factor for cardiovascular events, including heart disease and stroke. Improvements in glycemic control may improve health outcomes in people without diabetes.
Researchers identified 15 common food habits that significantly impact blood sugar control, surpassing the effectiveness of medication. By adopting these 'do's and avoiding specific 'don'ts,' individuals with diabetes can achieve normal blood sugar levels.
Researchers found two primitive protoglobulins in ancient archaea species, offering clues to the evolution of oxygen-based life. The discovery may aid in the search for future blood substitutes by understanding how transport proteins evolved to bind and release oxygen.
Researchers found that about 20% of un diagnosed participants were at risk for diabetes and 3.4% were diabetic. Shelter residents had lower hemoglobin A1c levels than those screened elsewhere, suggesting better health outcomes.
Researchers have developed a novel approach to modify alpha globin, potentially providing more effective treatments for sickle cell disease. Genetically engineered mice with the disease showed improved blood counts and extended lifespan after producing zeta globin.
Decitabine, an antimetabolite drug, has been found to improve fetal hemoglobin levels and reduce symptoms in patients with sickle cell disease who are resistant or intolerant of hydroxyurea. The study suggests that decitabine could be a viable alternative therapy for these patients.
Heme flooding can shut down cell membrane channels, killing neurons and constricting blood vessels. Researchers found a chemical called NS1619 restores channel function and may lead to a new treatment.
Researchers found that administering hydroxyurea to patients with severe forms of beta-thalassemia boosted hemoglobin levels and enabled five patients to stop undergoing transfusions. The treatment also improved quality of life for the children, who reported feeling better and more active.
Older adults with mild anemia are 1.5 times more likely to experience physical decline, according to a study published by the National Institute on Aging. Those with anemia or borderline anemia show greater declines in physical performance, including balance, walking speed, and chair rise ability.
A recent St. Jude study suggests that children with a higher proportion of sickled hemoglobin may develop 'twisted' arteries in the brain, which could increase their risk of stroke later in life. Researchers believe that this increased blood flow may damage arteries and lead to a higher risk of stroke among African Americans.
Researchers at UC Berkeley used a custom-made sensor to study the link between nerve cell activation and oxygen levels in brain tissue. The study found that initial decreases in oxygen levels precede increased neural activity, promising advancements in brain imaging techniques.
Researchers identified a complete iron-acquisition pathway in Staph. aureus, which also applies to Anthrax and Listeria. This discovery could lead to the development of new drugs to disrupt the pathway and prevent infection.
A Phase II clinical trial has shown that an hemoglobin raffimer may be effective in reducing the need for transfused blood during heart surgery. The study found that patients treated with the agent experienced no significant negative side effects, except for elevated blood pressures, which were manageable.
A CWRU anthropologist has discovered a distinct pattern of human adaptation to high-altitude hypoxia among the Ambaras people in Ethiopia, who have normal sea-level hemoglobin and oxygen saturations. This finding suggests that there are three patterns of adaptation to high-altitude living among indigenous populations.
A team of physicians at the University of Toronto successfully treated a pediatric patient with an autoimmune disease using a cell-free hemoglobin solution. This alternative provides oxygen-carrying capacity similar to blood cells, making it a viable option for children and Jehovah's Witnesses.
Researchers discover four distinct hemoglobin types in newborn Tammar wallabies, which persist for several days after birth. These embryonic-type hemoglobins have low oxygen affinity and do not function as tetrameric molecules.
A study of over 600 elderly women found that low hemoglobin levels are associated with a significant increase in the risk of mobility problems, such as difficulty walking or climbing stairs. The findings suggest that mild anemia may be a significant health issue for older women.
Decitabine has been shown to be effective in treating patients who don't respond to traditional treatment, reducing symptoms and improving quality of life. The study found that decitabine works by increasing fetal hemoglobin production, which can help alleviate the severity of sickle cell symptoms.
Scientists have successfully corrected sickle cell disease in mice using gene therapy by introducing an anti-sickling human beta-hemoglobin gene. The study, supported by the NHLBI, shows promising results with high expression of the gene in up to 99% of circulating red blood cells.
Red blood cells play a vital role in storing and releasing nitric oxide, a molecule that regulates blood flow and oxygen delivery. The findings could help improve understanding and treatment of diseases such as diabetes, sickle cell anemia, and high blood pressure.
Researchers have created artificial hemoglobin using genetic engineering techniques, showing great potential as an oxygen carrier for synthetic blood. The breakthrough could alleviate perennial blood bank shortages and provide a safe alternative for surgeries, transplants, and treating blood disorders.
Researchers used antisense oligonucleotides to block defective genes responsible for producing hemoglobin, restoring correct production of beta-globin and enabling cells to produce more hemoglobin. The correction could last for months and may be a simpler therapy than gene therapy.
Scientists have identified a biochemical link between ancient bacteria and modern mammalian hemoglobins, revealing that nematode worms use their strong hemoglobin to destroy oxygen. This unique function may also inspire the development of new cancer therapies by starving tumors of oxygen.
A common intestinal parasite has rewritten the understanding of hemoglobin's evolution and role in nature. The parasite reveals that hemoglobin evolved primarily to handle nitric oxide rather than oxygen.
Researchers at Massachusetts General Hospital have discovered that inhaled nitric oxide can reduce formation of sickle cells in patients with sickle cell disease, potentially interrupting crises. The treatment approach could lead to long-term, outpatient care for affected individuals.
Researchers found nitric oxide plays a central role in hemoglobin's function, regulating gas exchange and blood pressure. The discovery could lead to developing the first effective blood substitute and treating diseases associated with oxygen deficiency.
Researchers at Duke University Medical Center report a genetically modified version of hemoglobin as a safe blood substitute during surgery. The product, rHb 1.1, is designed to carry oxygen efficiently and eliminate disease transmission and immunosuppression, potentially reducing medical costs for patients and hospitals.